Skip to main content
OpenTrials
Completed

NCT Number: NCT04295733

Safety, Tolerability and Immunogenicity of 4CMenB Vaccine(2 Doses) in Adults With an Immunodeficiency

The meningococcal quadrivalent conjugate vaccine (MenACWY) and the licenced multicomponent MenB vaccine (Bexsero®) have already been included in the Italian childhood immunization programme and recommendations for high risk categories have been also implemented.

As by NIP, vaccination against MenB with either 4CMenB or fHbp-MenB is offered for free for several conditions including subjects with severe primary or secondary immunodeficiency.

In Liguria Region meningococcal vaccination is actively offered to several chronic conditions including asplenia, patients with lymphoproliferative disease (also HSCT), subject treated with anti-CD20 mAb and HIV-positive.

In Liguria Region there is a large diverse population with risk condition that, as by national and regional recommendation, receive meningococcal vaccination. For some of them, i.e. asplenic and complement deficiencies groups, evidence have been generated through an ad hoc clinical trial, while for other important groups there is clear need of immunogenicity data.

In the proposed study, the Investigators plan to administer two doses of MenB vaccine (Bexsero®), 1-2 months apart, to adult patients living in Genoa area and belonging to following categories:

* Bone marrow transplant (HSCT patient) * HIV positive * Alfa-CD20 subjects (i.e. Patients candidates for / in treatment with biologic drugs such as Rituximab).

Immunogenicity data will be then obtained from sera collected at the day of the first Bexsero dose and one month after the immunization course by Serum Bactericidal Activity (SBA) assay.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acquired Immunodeficiency

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

U.O.Igiene Ospedale Policlinico San Martino - IRCCS

Genoa, 16132, Italy

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Males and females 18 through 65 years of age at the time of enrollment who are high risk for IMD, including subjects with documented medical history of any of the following criteria:
  • Hematopoietic Stem Celi Transplantation (allogenic or autologous stem celi transplant)
  • HIV infection
  • candidate for / in treatment (ongoing) with biological drugs such as monoclonal antibodies anti CD- 20 (rituximab or ocrelizumab)
  • Written informed consent obtained from the subject (or legal representative).
  • Subjects (or legal representative) who are able to comprehend all procedures and to comply with the study requirements

Exclusion criteria

  • Subjects not able to understand and to adhere to ali study procedures
  • Subjects aged <18 or >65 years
  • Known or suspected allergy/hypersensitivity to any vaccine component
  • History of serious adverse reaction to any vaccine
  • Administration of immunoglobulins and/or any blood products within 3 months prior to enrollment or planned administration during the entire study period
  • History of any meningococcal group B vaccination or having been diagnosed with meningococcal disease ever before
  • Stem celi transplantation within 6 months before the enrollment to the study
  • HIV-infected patients with detectable viral load (>50 copies/mL) and/or CD4 celi count < 200 cells/mm3 in the last 6 months
  • Receipt of any vaccine within 28 (for live vaccines) or 14 (for no-live vaccines) days prior to study vaccination
  • Planned vaccination (other than the study vaccination) during the entire study period
  • Fever or any acute disease or infection within 3 days prior to vaccination
  • Receipt of any antibiotics within 3 days before enrollment
  • Coagulation disorder contraindicating intramuscular vaccination Any condition that in the opinion of the investigator would pose a health risk to the subject if enrolled or could interfere with the study procedures
  • Current participation to another investigational study or planned enrollment to an investigational during the entire study period
  • Planned surgery or hospitalization during the entire study period
  • Subjects who participated in Cohort 1, 2 or 3, cannot be included in other different cohorts
  • Pregnancy or breastfeeding (asking the woman to sign a declaration that she is not pregnant or breastfeeding).
  • Any contraindication to the study vaccine (Bexsero®) as specified in the Summary of Product Characteristics.

Treatment and study plan

4CMenB (Bexsero®) vaccine

Biological

Participants will receive 2 doses of 4CMenB (Bexsero®) vaccine administered intramuscularly 1-2 months apart

Primary outcomes

  1. hSBA geometries mean titres (GMTs) against relevant MenB strains

    Time frame: baseline (Visit 1) and one month after the second vaccination (Visit3).

    hSBA geometries mean titres (GMTs) against relevant MenB strains

  2. 4 fold increase in hSBA against relevant MenB

    Time frame: Baseline to one month after the second vaccination (Visit3)

    The proportion of subjects with at least 4 fold increase in hSBA against relevant MenB strains from baseline to one month after the second vaccination (Visit3)

  3. hSBA titres >1:4 against relevant MenB strains at Visit3 (one month after the second vaccination)

    Time frame: One month after the second vaccination (Visit3)

    The proportion of subjects with "protective" hSBA titres >1:4 against relevant MenB strains at Visit3 (one month after the second vaccination).

Secondary outcomes

  1. Local and systemic AEs

    Time frame: 7 days (including the day of vaccination) after Visits 1 and 2.

    The incidence of subjects with solicited local and systemic AEs (Pain, Erythema, Swelling, Induration, Fever -body temperature ~38.0°C-, Nausea, Myalgia, Arthralgia, Headache, Fatigue) up to 7 days (including the day of vaccination) after Visits 1 and 2.

  2. Unsolicited AEs

    Time frame: 7 days (including the day of vaccination) after Visits 1 and 2.

    The incidence of subjects with any other unsolicited AEs up to 7 days (including the day of vaccination) after Visits 1 and 2.

  3. SAEs and AEs leading to withdrawal and medically attended visits throughout the study period

    Time frame: An average of 15 months (from the day of first vaccination to the end of the study)

    The incidence of subjects with SAEs and AEs leading to withdrawal and medically attended visits throughout the study period

Sponsors and collaborators

Lead sponsor

Ospedale Policlinico San Martino

Other

Collaborators

  • GlaxoSmithKline

Registry information

Official study title

Evaluation of Safety, Tolerability and Immunogenicity of Two Doses of the 4CMenB Vaccine in Adults With an Immunodeficiency

Acronym: 4CMenB

Important dates

Study start
2020
Primary completion
2024
Study completion
2024
First posted
Mar 4, 2020
Registry last updated
Jan 22, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.